Trump Hails Regeneron Deal as First Round of Pharma Pricing Agreements Closes

The Trump administration on Thursday announced completion of a landmark pricing agreement with Regeneron Pharmaceuticals, marking what the White House described as the culmination of its first round of pharmaceutical negotiating deals. The announcement positions the Regeneron accord as the final piece of an initial batch of 17 deals sought by the administration, representing a significant milestone in the president's drug pricing agenda.

Under the private agreement, Regeneron committed to reducing drug prices for Medicaid, offering its cholesterol treatment Praluent at $225 through the TrumpRx program, and investing $27 billion in domestic drug development. The deal also coincided with FDA approval of Otarmeni, Regeneron's gene therapy for a rare form of hearing loss, which became the first treatment greenlit under the agency's new National Priority Voucher program. Clinical trials demonstrated modest hearing improvements in patients, though the therapy has drawn criticism from portions of the Deaf community. Regeneron has pledged to provide Otarmeni at no cost to American patients.

The agreement signals the administration's intent to expand its pharmaceutical pricing framework, with Trump promising additional deals ahead. The deal structure—tying drug pricing concessions to manufacturing investment commitments—suggests an approach that links cost reduction to domestic production incentives. Regeneron's strategic positioning as the final announced deal in this initial round establishes a template that could shape future negotiations with other major pharmaceutical manufacturers.